



myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) study. *J Am Coll Cardiol*. 2007;49:1772-1780.

21. Wilcox R, Boussier MG, Betteridge DJ, et al. Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke: results from PROactive (PROspective pioglitazone clinical trial in macrovascular events 04). *Stroke*. 2007;38:865-873.

22. Young LH, Viscoli CM, Inzucchi SE, et al. Cardiac outcomes after ischemic stroke or transient ischemic attack: effects of pioglitazone in patients with insulin resistance without diabetes mellitus. *Circulation*. 2017;135:1882-1893.

23. Vaccaro O, Masulli M, Nicolucci A, et al. Effects on their incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial. *Lancet Diabetes Endocrinol*. 2017;5:887-897.

24. Tzoulaki I, Molokhia M, Curcin V, et al. Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database. *BMJ*. 2009;339:b4731.

25. Morgan CL, Poole CD, Evans M, et al. What next after metformin? A retrospective evaluation of the outcome of second-line, glucose-lowering therapies in people with type 2 diabetes. *J Clin Endocr Metab*. 2012;97:4605-4612.

26. Morgan CL, Inzucchi SE, Pulles J, et al. Impact of treatment with pioglitazone on stroke outcomes: a real world database analysis. *Diabetes Obes Metab*. 2018;20:2140-2147.

27. Tseng CH. Pioglitazone Reduces Dementia Risk in Patients with Type 2 Diabetes Mellitus: A Retrospective Cohort Analysis. *J Clin Med*. 2018;7:306.

28. DeFronzo RA. Combination therapy with GLP-1 receptor agonist and SGLT2 inhibitor. *Diabetes Obes Metab*. 2017;19:1353-1362.

29. Karasek D. Vliv antidiabetické léčby na kost nemocných s DM 2. typu. *Vnitř Lek*. 2016;62:582-587.

30. SÚKL upozorňuje: pioglitazon a riziko kostních fraktur u žen. *Farmakoterapeutické informace* 5/2007.

31. Adil M, Khan RA, Ghosh P, et al. Pioglitazone and risk of bladder cancer in type 2 diabetes mellitus patients: A systematic literature review and meta-analysis of observational studies using real-world data. *Clin Epidemiol Glob Health*. 2018;6:61-68.

32. American Diabetes Association Professional Practice Committee, Draznin B, Aroda VR, Bakris G, et al. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2022. *Diabetes Care*. 2022;45(Suppl 1):S125-S143. doi: 10.2337/dc22-S009. PMID: 34964831.